Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Rodriguez-Valverde

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Annals of the Rheumatic Diseases|December 17, 2008
The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trialM Schiff, C Pritchard, J E Huffstutter, et al.
British Journal of Rheumatology|August 1, 1995
Menstrual disorders in girls with systemic lupus erythematosus treated with cyclophosphamideM R Gonzalez-Crespo, J J Gomez-Reino, R Merino, et al.
Clinical and Experimental Rheumatology|August 4, 2009
Interleukin-12 gene polymorphisim in patients with giant cell arteritis, polymyalgia rheumatica and elderly-onset rheumatoid arthritisL Alvarez-Rodriguez, V M Martínez-Taboada, M López-Hoyos, et al.
Annals of the Rheumatic Diseases|June 30, 2000
Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritisJ S Smolen, F C Breedveld, G R Burmester, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Annals of the Rheumatic Diseases|December 17, 2008
The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trialM Schiff, C Pritchard, J E Huffstutter, et al.
British Journal of Rheumatology|August 1, 1995
Menstrual disorders in girls with systemic lupus erythematosus treated with cyclophosphamideM R Gonzalez-Crespo, J J Gomez-Reino, R Merino, et al.
Clinical and Experimental Rheumatology|August 4, 2009
Interleukin-12 gene polymorphisim in patients with giant cell arteritis, polymyalgia rheumatica and elderly-onset rheumatoid arthritisL Alvarez-Rodriguez, V M Martínez-Taboada, M López-Hoyos, et al.
Annals of the Rheumatic Diseases|June 30, 2000
Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritisJ S Smolen, F C Breedveld, G R Burmester, et al.
Pageof 5